SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-23-056503
Filing Date
2023-12-06
Accepted
2023-12-06 16:01:15
Documents
14
Period of Report
2023-12-06
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20016120_8k.htm   iXBRL 8-K 31372
2 EXHIBIT 99.1 ef20016120_ex99-1.htm EX-99.1 41858
6 image01.jpg GRAPHIC 2565
  Complete submission text file 0001140361-23-056503.txt   220167

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA gyre-20231206.xsd EX-101.SCH 3907
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE gyre-20231206_lab.xml EX-101.LAB 22546
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE gyre-20231206_pre.xml EX-101.PRE 16072
8 EXTRACTED XBRL INSTANCE DOCUMENT ef20016120_8k_htm.xml XML 4206
Mailing Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130
Business Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130 (619) 949-3681
GYRE THERAPEUTICS, INC. (Filer) CIK: 0001124105 (see all company filings)

IRS No.: 562020050 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51173 | Film No.: 231469572
SIC: 2834 Pharmaceutical Preparations